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Patients with asthma with obesity experience severe symptoms, are unresponsive to conventional 
asthma treatment, and lack proper pharmacotherapy. Empagliflozin and dulaglutide, developed 
for diabetes, reduce weight, decrease insulin resistance, and exert additive effects. We evaluated 
the efficacy of empagliflozin, dulaglutide, and their combination on obesity-induced airway 
hyperresponsiveness (AHR) and lung fibrosis using a murine model. We assigned C57BL/6J mice to 
five groups: control, high-fat diet (HFD), and HFD with empagliflozin, dulaglutide, or both. Mice 
received a 12-week HFD, empagliflozin (5 days/week, oral gavage), and dulaglutide (once weekly, 
intraperitoneally). Both drugs significantly attenuated HFD-induced weight increase, abnormal glucose 
metabolism, and abnormal serum levels of leptin and insulin, and co-treatment was more effective. 
Both drugs significantly alleviated HFD-induced AHR, increased macrophages in bronchoalveolar lavage 
fluid (BALF), and co-treatment was more effective on AHR. HFD-induced lung fibrosis was decreased by 
both drugs alone and combined. HFD induced interleukin (IL)-17, transforming growth factor (TGF)-β1, 
and IL-1β mRNA and protein expression, which was significantly reduced by empagliflozin, dulaglutide, 
and their combination. Tumour necrosis factor (TNF)-α and IL-6 showed similar patterns without 
significant differences. HFD-enhanced T helper (Th) 1 and Th17 cell differentiation was improved by 
both drugs. Empagliflozin and dulaglutide could be a promising therapy for obesity-induced asthma and 
showed additive effects in combination.
Obesity has been recognized as an important risk and aggravating factor for asthma1,2. Physical limitation on 
motion of lung volume, metabolic abnormality including insulin resistance, innate immunity, non-T helper (Th) 
2 type inflammatory signals, and fibrosis are suggested to be main mechanisms of obesity-induced asthma devel-
opment and exacerbation3. With the increased prevalence of obesity and asthma, obesity-induced asthma has 
emerged as a serious problem that needs to be addressed1,4. Patients with asthma who have obesity experience 
severe symptoms, do not respond to conventional asthma treatment including inhaled corticosteroids, and pro-
gress to a condition with a poor prognosis5,6. Current recommendations to treat obesity-induced asthma are 
mainly lifestyle modifications to lose weight and bariatric surgery to reduce energy intake7,8. Although some 
anti-obesity drugs have shown significant effects in controlling asthma in previous studies9, there are no drugs 
which are clinically used for the treatment of obesity-induced asthma. Until now, numerous researchers are cur-
rently working on a new candidate drug10.
Some anti-obesity drugs have emerged. Empagliflozin, a sodium/glucose cotransporter (SGLT) 2 inhibitor 
developed to treat diabetes, acts by inhibiting glucose reabsorption in the kidney to control glucose levels with-
out hypoglycaemic side effects, leading to improvement of insulin resistance and weight loss11. Dulaglutide, a 
glucagon-like peptide (GLP) 1 receptor agonist, was also developed to control glucose levels. It increases signal-
ing on insulin secretion, inhibits glucagon release when glucose levels are elevated, and delays gastric emptying, 
leading to weight loss12. The combination of an SGLT2 inhibitor and a GLP1 agonist is known to have synergic 
effects on glucose control and weight reduction13. We expected these two anti-obesity drugs to improve disease 
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control of obesity-induced asthma. We also expected the combination of both drugs to be more effective than 
monotherapy.
We aimed to determine whether empagliflozin and dulaglutide alone or combined would be effective against 
obesity-induced airway hyperresponsiveness (AHR) and lung fibrosis using a murine model.
Results
Empagliflozin and dulaglutide improved high fat diet (HFD)-induced weight increase. Compared 
to the control group fed a normal chow diet with a mean weight of 29.7 g, the HFD group showed a tremendous 
increase in weight at 50.9 g on the final date, which was 171.4% of the average weight of the control group (Fig. 1A). 
The gross appearance and volume of the organs including the lung, liver, and adipose tissue were much larger in 
the HFD group than they were in the control group (Fig. 1B). The final weights of the HFD-induced obesity with 
empagliflozin (HFD/EMP), with dulaglutide (HFD/DUL), and with a combination of empagliflozin and dulaglu-
tide (HFD/combi) groups were 47.6, 42.8, and 40.4 g (160.2, 144.1, and 136.0% of the average weight of the control 
group), respectively. Although empagliflozin alone did not significantly reduce the weight increase, dulaglutide 
alone and combined with empagliflozin were significantly effective in reducing the weight increase (Fig. 1A).
Figure 1. We designed 5 groups as follows: normal diet control (n = 6), HFD-induced obesity (n = 7), HFD/
EMP (n = 5), HFD/DUL (n = 7), and HFD/combi (n = 7). Weight changes among groups (A), gross appearance 
and volume of internal organ in control group (left) and HFD group (right) (B), baseline fasting glucose level 
among groups at week 0 (C), fasting glucose level among groups at week 12 (D), baseline GTT-AUC among 
groups at week 0 (E), GTT-AUC among groups at week 12 (F), serum level of leptin (G) and insulin (H) among 
groups at week 12. Repeated-measures analysis of variance (ANOVA) followed by a post-hoc Bonferroni test 
was used in Fig. 2A and one-way ANOVA followed by a post-hoc Bonferroni test was used in Fig. 2C-F. HFD, 
high-fat diet; EMP, empagliflozin; DUL, dulaglutide; combi, combination of EMP and DUL; GTT, glucose 
tolerance test; AUC, area under the curve.
Figure 2. Airway hyperresponsiveness (AHR, A) and bronchoalveolar lavage fluid (BALF) cell count 
(B) among groups. Repeated-measures analysis of variance (ANOVA) followed by a post-hoc Bonferroni test 
was used in Fig. 3A and one-way ANOVA followed by a post-hoc Bonferroni test was used in Fig. 3B. HFD, 
high-fat diet; EMP, empagliflozin; DUL, dulaglutide; combi, combination of EMP and DUL.
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Empagliflozin and dulaglutide improved HFD-induced metabolic abnormality. Baseline fasting 
glucose and glucose tolerance test (GTT)-area under the curve (AUC) assessed at week 0 were not different 
among the groups; however, after 12 weeks, the values were significantly higher in the HFD group than in the 
control group. Empagliflozin, dulaglutide, and their combination significantly reduced fasting glucose level. In 
addition, co-therapy more effectively reduced the fasting glucose than empagliflozin alone did. Empagliflozin 
and the co-treatment reduced the GTT-AUC; however, dulaglutide was not significantly effective (Fig. 1C–F). 
Serum levels of leptin (Fig. 1G) and insulin (Fig. 1H) were significantly elevated in HFD group compared to that 
in control group, however, it was significantly reduced in all the treatment group.
Figure 3. Histopathological assessment using haematoxylin and eosin (H&E), periodic acid-Schiff (PAS), 
and Mason’s trichrome (MT) staining (×200) (A), quantitative fibrosis area assessed using MT staining (B), 
and hydroxyproline level (C) among groups. Fibrosis was more predominantly observed in peribronchial and 
perivascular area compared that in lung parenchymal lesion in MT staining (×400) (D). One-way ANOVA 
followed by a post-hoc Bonferroni test was used in Fig. 4B,C. HFD, high-fat diet; EMP, empagliflozin; DUL, 
dulaglutide; combi, co-treatment with EMP and DUL.
Figure 4. Cytokine mRNA expression (A–E), cytokine level (F–J), and Th cell differentiation (K, L) among 
groups. One-way ANOVA followed by a post-hoc Bonferroni test was used in Fig. 5. HFD, high-fat diet; EMP, 
empagliflozin; DUL, dulaglutide.
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Empagliflozin and dulaglutide alleviated HFD-induced AHR and airway inflammation. 
Compared to the control group, the HFD group showed significant AHR. Empagliflozin, dulaglutide, and the 
co-treatment significantly alleviated HFD-induced AHR. However, the AHR in the HFD/EMP and HFD/DUL 
groups was significantly different from that in the control group. In addition, the HFD/combi group showed 
a further reduction in the AHR to levels comparable to that of the control group (Fig. 2A). Compared to the 
control group, the HFD group showed a significant increase in bronchoalveolar lavage fluid (BALF) cells with 
macrophage dominance. Empagliflozin, dulaglutide, and the combination significantly alleviated HFD-induced 
increase in BALF cells, especially macrophages and neutrophils (Fig. 2B).
Empagliflozin and dulaglutide alleviated HFD-induced fibrosis. The results of histopathologi-
cal analysis performed using haematoxylin and eosin (H&E) and periodic acid-Schiff (PAS) staining were not 
different among the groups, which showed similar cellular proliferation and infiltration and goblet cell hyper-
plasia. However, Masson’s trichrome (MT) staining revealed that HFD induced significant fibrosis compared 
to the control group. Empagliflozin, dulaglutide, and the co-treatment significantly alleviated HFD-induced 
fibrosis (Fig. 3A). The fibrotic area in the HFD group was significantly broader than that in the control group. 
Empagliflozin, dulaglutide, and the co-treatment significantly alleviated the extent of HFD-induced fibrosis area 
to levels in the control group (Fig. 3B). Hydroxyproline level significantly increased in the HFD group compared 
to that in the control group and this effect was significantly improved in the HFD/combi group (Fig. 3C). Fibrosis 
was more predominantly observed in peribronchial and perivascular area compared that in lung parenchymal 
lesion (Fig. 3D).
Empagliflozin and dulaglutide improved HFD-induced increase in cytokine mRNA expression. 
We assessed cytokine mRNA expression to evaluate the effects of the drugs on mRNA inflammatory signals. 
Interleukin (IL)-17 and transforming growth factor (TGF)-β1 mRNA expression significantly increased in 
the HFD group compared to the control group, whereas empagliflozin, dulaglutide, and the co-treatment sig-
nificantly reduced these levels to those in the control group. IL-1β, tumour necrosis factor (TNF)-α, and IL-6 
mRNAs showed a similar pattern; however, they were not statistically significant (Fig. 4A–E).
Empagliflozin and dulaglutide improved HFD induced cytokine productions. Cytokine levels in 
lung homogenates were assessed using two site-ELISA kits to evaluate the effects of drugs on inflammatory pro-
tein levels. IL-17, TGF-β1, and IL-1β levels, which significantly increased in the HFD group compared to the con-
trol group, were significantly reduced in the HFD/EMP, HFD/DUL, and HFD/combi groups to the control group 
levels. TNF-α and IL-6 showed a similar pattern but no statistical significance was found with empagliflozin or 
dulaglutide. Only the co-treatment significantly reduced TNF-α and IL-6 levels compared to those of the HFD 
group. In addition, the HFD/combi group showed significantly reduced IL-6 levels compared to that in the HFD/
EMP and HFD/DUL groups (Fig. 4F–J).
Empagliflozin and dulaglutide improved HFD-induced increase in Th cell differentiation. Th cell 
differentiation was analysed to determine the effects of drugs on cellular inflammatory signals. HFD induced active 
differentiation of Th1 and Th17 cells, which was significantly decreased by empagliflozin, dulaglutide, and the 
co-treatment. In addition, the co-treatment showed higher effects than did empagliflozin alone and dulaglutide 
alone (Fig. 4K,L).
Discussion
This is the first study to confirm that empagliflozin and dulaglutide improve AHR and fibrosis, thereby suppress-
ing obesity-induced asthma in a murine model. Obesity alone (weight increase ≥145%) without any allergenic 
sensitization can induce significant asthma with non-Th2 type non-eosinophilic features14,15. Various mecha-
nisms including metabolic abnormality, innate immunity, and specific cytokines have been implicated in these 
effects3. Weight-loss interventions have been first postulated as therapeutic options to improve asthma outcomes 
in obesity-induced asthma patients. There are emerging studies on the effects of lifestyle modification and bariat-
ric surgery on obesity-induced asthma; however, few have investigated the effects of pharmacotherapy16. To date, 
no anti-obesity drugs are used to treat obesity-induced asthma, clinically. For the first time, we demonstrated the 
potential usefulness of the anti-obesity drugs, empagliflozin and dulaglutide, in treating obesity-induced asthma 
using an HFD-induced obesity murine model.
Empagliflozin and dulaglutide were originally developed to manage diabetes11,12. Then, this study showed 
significant improvement of glucose metabolism in both two drugs, although EMP did not reach significant weight 
loss. However, these drugs have additional weight-loss effects without hypoglycaemic adverse reaction. Contrary 
to EMP, DUL had direct effect on gastric emptying, and has more strong effects on weight loss. We also showed 
Figure 5. Scheme of study. HFD, high-fat diet; OG, oral gavage; IP, intraperitoneal.
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similar results in this study, moreover we showed additive effects on weight loss using both drugs. Only one 
clinical study has suggested that the anti-obesity drugs, sibutramine and orlistat, combined with dietary restric-
tion could improve asthma control9. Contrary to these older anti-obesity drugs, empagliflozin and dulaglutide 
have no psychotropic or gastrointestinal stimulating effects; therefore, they can be used safely for a relatively 
prolonged period11,12. Therefore, we hypothesised that these drugs could be promising candidates to manage 
obesity-induced asthma in clinical use. We demonstrated the plausibility that these two drugs could significantly 
reduce weight increase, which attenuated HFD-induced inflammation, lung fibrosis, and AHR: indirect effects.
We also showed that co-treatment with these two drugs had additive effects on HFD-induced AHR and fibro-
sis. This may have been mediated by superior weight reduction of combination compared to that of either empag-
liflozin and dulaglutide. Additive effect of the co-treatment on weight reduction were also revealed in a previous 
human study13. Because of this effect, contrary to each monotherapy, the co-therapy completely prevented the 
development of AHR and fibrosis by HFD. In summary, we confirmed that this additive effect is also potentially 
effective in the management of obesity-induced adsthma via weight reduction.
Metabolic abnormality has been suggested as the mechanism of obesity-induced asthma. Adipokines, includ-
ing adiponectin and leptin, secreted by adipose tissues are important hormones for regulating metabolic process, 
energy homeostasis, and inflammation. Reduced adiponectin and increased leptin level, which are frequently 
observed in obesity could induce AHR17,18. Hyperglycaemia and insulin resistance are also suggested to be risk 
factors for asthma and lung fibrosis19,20. Previous studies have showed that obesity induce impairment of insulin 
signaling, which can lead to bronchoconstriction, fibrosis, and AHR21,22. Empagliflozin and dulaglutide restored 
the metabolic abnormality, including leptin and insulin levels, in this study model. Both the weight loss and 
restorative effects on the metabolic abnormality may alleviate obesity-induced asthma.
This study showed that the weight loss effects of empagliflozin are slightly weaker than those of dulaglutide 
and their combination; however, empagliflozin was also significantly effective against AHR and fibrosis. Then, we 
can assume that weight reduction and improvement of glucose metabolism alone does not seem to contribute to 
this mechanism. Obesity leads to asthma via various mechanisms including inflammatory signalling and fibrotic 
changes; therefore, recent studies have revealed that anti-inflammatory or anti-fibrotic drugs including roflu-
milast, anti-IL-17 and anti-IL-1β antibodies could have significant effects on obesity-induced asthma without 
significant weight loss10,23,24. Empagliflozin and dulaglutide have anti-inflammatory effects by direct and indirect 
effects on inflammatory signalling, oxidative stress, and cytokine production14,25–27. In addition, the these drugs 
can result in anti-fibrosis effects22. We think the additional anti-inflammatory and anti-fibrotic effects of these 
drugs might enhance their positive treatment effects on obesity-induced asthma: direct effect.
We also showed that obesity did not induce overt inflammation in airway and lung parenchyme in this study. 
Many previous studies have described that obesity lead to changes of adipokines, increases of cytokine level, 
increases of fibrosis, however it did not lead to cellular infiltration in lung tissue10,14,28. This phenomenon had 
called ‘low-grade systemic inflammation’ or ‘pauci inflammation’14. This study also showed similar results to 
previous studies.
Obesity-induced asthma presents with severe symptoms that do not respond to conventional asthma treat-
ment, which subsequently proceeds to poor outcomes in patients5,6. Currently, there is no specific drug for the 
management of obesity-induced asthma and the increasing prevalence of this condition has led to an urgent 
requirement for the development of an effective treatment1,4. We propose that empagliflozin and dulaglutide, 
alone and combined could be used to safely treat obesity-induced asthma. This new pharmacotherapy might 
contribute to reducing the medical cost associated with unresponsiveness to conventional therapies and improve 
the clinical efforts to treat obesity-induced asthma.
Obesity accompanies various comorbid diseases including hypertension, diabetes, cardiovascular disease, 
renal insufficiency, and even cancer, and it causes tremendous economic burden29,30. Empagliflozin and dulaglu-
tide could improve metabolic abnormality, lead to weight loss, and contribute to treating other obesity-related 
comorbid diseases31,32. Empagliflozin has shown protective effects on the cardiovascular and renal system, similar 
to the effects of dulaglutide33. We believe that these drugs could be prescribed to asthma patients with obesity and 
could be helpful in controlling other obesity-related comorbidities.
This study has some limitations. First, the specific action mechanisms of empagliflozin and dulaglutide on the 
obesity-induced asthma were not revealed. We suggest numerous possible mechanisms; weight loss, restoration 
of metabolic abnormality, anti-inflammatory effects, and anti-fibrotic effects that may contribute to the treatment 
efficacy. However, further studies using inhibitors of specific cytokine or molecules are required to determine the 
detailed mechanisms. Second, a multimodal approach such as the combination of pharmacotherapy, reduction 
of dietary intake, or exercise or a combination of these activities may be more helpful to manage obesity-induced 
asthma than drug treatment alone, and further studies are needed to prove the hypothesis. Third, other effects 
of these drugs on the liver, heart, and kidney were not investigated and this should be a focus of future investiga-
tions. In addition, previous study showed obesity impairs macrophage and monocyte efferocytosis, and it reduces 
glucocorticoid responsiveness34. If improvement of glucocorticoid responsiveness after treatment of study drugs 
was observed, it would be interesting. Last, we used only male murine model, because we could not obtain suf-
ficient weight gain to induced significant AHR and fibrosis using female murine model in preliminary model. 
Although there have been controversial, some clinical studies have revealed that female is more susceptible to 
obesity associated asthma than male35. We should carefully interpret results of this study based on them.
This is the first study to indicate that empagliflozin and dulaglutide could be promising candidates in the 
treatment of obesity-induced AHR and fibrosis, using a murine HFD model. Weight loss, restoration of meta-
bolic abnormality, anti-inflammatory, and anti-fibrotic effects of these drugs may be involved in the mechanisms. 
Co-treatment with these two drugs had an additive effects and further randomized clinical trials may be needed 
to prove these findings.
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Methods
Animals and study design. We assigned mice to the following five groups (n = 5–7 per group): normal 
diet control (n = 6), HFD-induced obesity (n = 7), HFD/EMP (n = 5), HFD/DUL (n = 7), and HFD/combi 
(n = 7). The study scheme is shown in Fig. 5. All the mice were maintained in conventional animal facilities 
under standard conditions (room temperature, 21–24 °C; relative humidity, 45–70%; 12-h light/dark cycle), 
which has been fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care 
International. The 4-week-old male C57BL/6 mice (Japan-SLC, Hamamatsu, Japan) were fed an HFD (D12492; 
Research Diets, Inc., New Brunswick, USA; fat accounting for 60% of the calories) for 12 weeks to establish 
the HFD-induced obesity model. Lean mice in the control group were fed a normal chow diet (D12450B; fat 
accounting for 10%). Empagliflozin (Jardiance, 10 mg·kg−1·day−1, Boehringer Ingelheim, Germany) dissolved 
with 0.5% hydroxyethylcellulose (Sigma-Aldrich, Germany) or the solvent was administered by oral gavage five 
times per week. Dulaglutide (Trulicity, 0.6 mg·kg−1·week−1, Eli Lilly, IN, USA) dissolved with 0.9% saline or the 
solvent was administered intraperitoneally once a week. The HFD/combi group was co-administered empagli-
flozin (10 mg·kg−1·day−1) and a reduced dose of dulaglutide (0.3 mg·kg−1·week−1). In control group and HFD 
group, solvent of both two drugs was administered according to the above protocol. In HFD/EMP group, empag-
liflozin and solvent of dulaglutide were administered according to the above protocol. In HFD/DUL group, 
dulaglutide and solvent of empagliflozin were treated along with the above protocol. The dose in empagliflozin 
(10 mg·kg−1·day−1) and dulaglutide (0.6 mg·kg−1·week−1) were selected based on the previous studies36,37, and the 
combination dose of dulaglutide (0.6 mg·kg−1·week−1) was chosen based on our preliminary studies. The study 
protocol was approved by the Institutional Animal Care and Use Committee of the Yonsei University College of 
Medicine (Seoul, Korea), which has been fully accredited by the Association for Assessment and Accreditation 
of Laboratory Animal Care International, and conducted according to the relevant guidelines and regulations of 
the institution.
Fasting glucose level, GTT, serum levels of leptin and insulin. The fasting glucose level and oral 
GTT were performed at baseline week 0 and final week 12. Mice were starved overnight for the fasting glu-
cose level analysis and GTT. Fasting glucose was measured before the start of GTT. The GTT was performed 
after orally administering glucose (2 g/kg body weight; Sigma-Aldrich, St. Louis, MO, USA). Blood from the tail 
vein was measured at 0, 30, 60, 90, and 120 minutes after glucose injection to determine glucose level using the 
Accu-Check glucometer (Roche, Mannheim, Germany). Serum levels of leptin (R&D system, Inc., Minneapolis, 
MN) and insulin (Alpc, Salem, NH, USA) on the final date were measured using commercial ELISA kit according 
to the suggested protocol, respectively.
Measurement of methacholine AHR. The mice were anesthetized with pentobarbital sodium (50 mg/kg; 
Hanlim Pharma Co., Seoul, Korea) by intraperitoneal injection 48 h after the last challenge. An 18-gauge cannula 
was inserted into each anesthetized mouse via tracheostomy, and then the mouse was connected to a ventilator. 
AHR in response to various concentrations of inhaled aerosolized methacholine (MCh, 6.25, 12.5, 25.0, 50.0, 
and 100.0 mg/mL; Sigma-Aldrich) was measured using a forced oscillation technique (FlexiVent® 5.1; SCIREQ, 
Montreal, Canada) as previously described38.
Collection and processing of BALF. To collect BALF, the mouse lungs were irrigated with 1 mL Hank’s 
balanced salt solution (HBSS, Thermo Fisher Scientific, Waltham, MA, USA) through the tracheal tube and the 
total number of cells was counted using a haemocytometer. The collected BALF samples were centrifuged for 
3 min at 10,000 rpm and 4 °C and the supernatants were stored at −80 °C. The whole cell pellets were resuspended 
in HBSS, and BALF cell smears were prepared by cytocentrifugation (Cytospin 3, Thermo, Billerica, MA, USA). 
The cytocentrifuged slides were stained with Leukostat (Fisher Diagnostics, Fair Lawn, NJ, USA) to count at least 
200 inflammatory cells as previously described38.
Histological analysis. The left lungs of the mice were fixed in 4% formalin and embedded in paraffin. 
Lung sections were cut and stained with H&E for general examination, PAS to measure goblet cell hyperplasia, 
and MT to assess fibrosis as previously described39. Tissue sections were examined using an Olympus BX40 
microscope in conjunction with an Olympus U-TV0.63XC digital camera (Olympus BX53F, Center Valley, PA, 
USA). Images were acquired using the CellSens standard 1.6 image software. Fibrosis was quantitatively analysed 
using Metamorph® (Molecular Devices, Sunnyvale, CA, USA). The fibrotic area was assessed by measuring the 
colour-pixel count over the pre-set threshold colour for the entire field containing several bronchial tubes on 
MT-stained slides at 200× magnification. In addition, a commercially available hydroxyproline assay kit (Cell 
Biolabs, Inc., San Diego, USA) was used to quantify fibrosis in lung homogenates.
Enzyme-linked immunosorbent assay. To analyse cytokine levels, the right lung tissues were homoge-
nized with 50 mg/mL tissue protein extraction buffer (ThermoFisher Scientific Inc., Rockford, IL, USA) using a 
tissue homogenizer (Biospec Products, Bartlesville, OK, USA). After incubation for 30 min on ice, homogenates 
were centrifuged at 14,000 rpm for 10 min. Supernatants of lung homogenates were collected and stored at −80°C 
for measurement of cytokine levels. Concentrations of IL-17, TGF-β1, IL-1β, TNF-α, and IL-6 in lung homoge-
nate were measured using an enzyme-linked immunosorbent assay (ELISA, R&D Systems, San Diego, CA, USA) 
according to the manufacturer’s instructions.
RNA extraction and real-time polymerase chain reaction (PCR). Total RNA was extracted from 
lung tissues using in TRIzol® reagent (Ambion, Life technologies, Carlsbad, CA, USA) by homogenization using 
a tissue homogenizer (T10 basic ULTRA-TURRAX®, IKA, Staufen, Germany) according to the manufacturer’s 
instructions. Reverse transcription was performed using reverse transcriptase (Invitrogen, Carlsbad, CA, USA) 
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primed with oligo (dT) primer. The synthesized cDNAs were amplified using the SYBR® green PCR master mix 
(BioRad, California, USA) and forward and reverse primers (Bioneer, Daejeon, Korea) using a real-time PCR sys-
tem (StepOnePlus, Applied Biosystems, Foster City, CA, USA). All the PCR experiments were performed under 
the following conditions: 95 °C for 5 min, 95 °C for 15 s, and 60 °C for 45 s for up to 40 cycles.
Flow cytometry. Cells obtained from the lung tissues were stained with fluorescent dye-conjugated CD3 
(T-cell marker), CD4 (T helper cell marker), C-X-C motif chemokine receptor 3 (CXCR3, Th1 cell marker), 
C-C motif chemokine receptor 4 (CCR4, Th2 cell marker), CCR6 (Th17 cell marker), and CD8 (T cytotoxic cell 
marker) antibodies (eBiosciences, San Diego, CA, USA). Stained cells were measured using a BD FACSVerse™ 
flow cytometer and analysed using the FlowJo 8.3.3 software (BD Bioscience, San Jose, CA, USA).
Statistical analysis. All results are expressed as the mean ± standard error of mean. The weight change and 
AHR data among the groups were analysed using a repeated-measures analysis of variance (ANOVA) followed by 
a post-hoc Bonferroni test. One-way ANOVA followed by a post-hoc Bonferroni test was performed to compare 
the numeric variables among groups. The GTT-AUC was obtained as the calculated AUC of glucose level changes 
according to the time after GTT. We used the statistical package for the social sciences (SPSS) software version 
12.0 (SPSS Inc., Chicago, IL, USA) for the analyses and a P < 0.05 was considered statistically significant.
Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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